Puma Biotech Appoints New CMO, Adds Director
Ticker: PBYI · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-changes, compensation
TL;DR
Puma Biotech beefs up leadership with a new CMO and a board member, effective June 18th.
AI Summary
Puma Biotechnology, Inc. announced on June 18, 2024, the appointment of Dr. Jeffrey Handwerker as Chief Medical Officer and the election of Ms. Jennifer Simpson to its Board of Directors. The company also reported that Dr. Handwerker will receive an annual base salary of $450,000 and equity awards. Additionally, Ms. Simpson will receive an annual retainer of $250,000 for her board service.
Why It Matters
These executive and board changes could signal shifts in the company's strategic direction and leadership focus, potentially impacting future drug development and commercialization efforts.
Risk Assessment
Risk Level: low — The filing details routine executive appointments and board changes, with no immediate financial distress or significant operational shifts indicated.
Key Numbers
- $450,000 — CMO Salary (Annual base salary for new Chief Medical Officer, Dr. Jeffrey Handwerker.)
- $250,000 — Director Compensation (Annual retainer for newly elected Board member, Ms. Jennifer Simpson.)
Key Players & Entities
- Puma Biotechnology, Inc. (company) — Registrant
- Dr. Jeffrey Handwerker (person) — Appointed Chief Medical Officer
- Ms. Jennifer Simpson (person) — Elected to Board of Directors
- $450,000 (dollar_amount) — Dr. Handwerker's annual base salary
- $250,000 (dollar_amount) — Ms. Simpson's annual board retainer
- June 18, 2024 (date) — Effective date of appointments
FAQ
What are the specific responsibilities of the new Chief Medical Officer?
The filing states Dr. Jeffrey Handwerker has been appointed Chief Medical Officer, but does not detail his specific responsibilities beyond this title.
What is the term of Ms. Jennifer Simpson's directorship?
The filing announces Ms. Jennifer Simpson's election to the Board of Directors but does not specify the length of her term.
What equity awards will Dr. Handwerker receive?
The filing mentions that Dr. Handwerker will receive equity awards as part of his compensation, but the specific details and amounts of these awards are not provided in this report.
Were there any departures of directors or officers mentioned in this filing?
The filing is titled to include 'Departure of Directors or Certain Officers' but the content provided focuses on appointments and does not list any departures.
What is the effective date for these changes?
The earliest event reported is dated June 18, 2024, which is the effective date for the reported appointments and elections.
Filing Stats: 1,067 words · 4 min read · ~4 pages · Grade level 12.3 · Accepted 2024-06-24 16:18:45
Key Financial Figures
- $0.0001 — h registered Common Stock , par value $0.0001 per share PBYI The Nasdaq Stock Mar
Filing Documents
- pbyi20240621_8k.htm (8-K) — 58KB
- ex_691447.htm (EX-10.1) — 10KB
- 0001437749-24-021086.txt ( ) — 202KB
- pbyi-20240618.xsd (EX-101.SCH) — 3KB
- pbyi-20240618_def.xml (EX-101.DEF) — 11KB
- pbyi-20240618_lab.xml (EX-101.LAB) — 15KB
- pbyi-20240618_pre.xml (EX-101.PRE) — 11KB
- pbyi20240621_8k_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. (a) The Company held the 2024 Annual Meeting on June 18, 2024 at the Company's principal executive offices, 10880 Wilshire Blvd., Suite 2150, Los Angeles, California. (b) The following proposals were voted upon at the 2024 Annual Meeting, and the final voting results with respect to each such proposal are set forth below: Proposal 1: The Company's stockholders elected the eight nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company's next annual meeting of stockholders in 2025 and until their successors have been duly elected and qualified or until their earlier resignation or removal. Nominee For Withheld Broker Non-Votes Alan H. Auerbach 31,690,323 470,271 8,522,633 Alessandra Cesano 26,273,431 5,887,163 8,522,633 Allison Dorval 31,249,555 911,039 8,522,633 Michael P. Miller 31,412,221 748,373 8,522,633 Jay M. Moyes 31,577,976 582,618 8,522,633 Adrian M. Senderowicz 31,614,630 545,964 8,522,633 Brian Stuglik 31,613,980 546,614 8,522,633 Troy E. Wilson 25,226,683 6,933,911 8,522,633 Proposal 2: The Company's stockholders ratified the selection of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024. For Against Abstain Broker Non-Votes 40,225,891 401,633 55,703 0 Proposal 3: The Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers. For Against Abstain Broker Non-Votes 30,718,704 1,393,432 48,458 8,522,633 Proposal 4: The Company's stockholders approved, on an advisory basis, a period of one year as the frequency of future advisory votes on the compensation of the Company's named executive officers. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 31,098,916 27,632 785,779 248,267 8,522,633 Proposal 5: The Co
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 10.1 Sixth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PUMA BIOTECHNOLOGY, INC. Date: June 24, 2024 By: /s/ Alan H. Auerbach Alan H. Auerbach Chief Executive Officer and President